BTG Pactual Asset Management US’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.19M Buy
28,476
+5,598
+24% +$1.24M 0.54% 55
2025
Q4
$5.23M Sell
22,878
-784
-3% -$179K 0.51% 51
2025
Q3
$5.48M Buy
23,662
+13,439
+131% +$2.74M 0.26% 51
2025
Q2
$1.9M Buy
10,223
+385
+4% +$71.6K 0.21% 94
2025
Q1
$2.06M Buy
9,838
+2,035
+26% +$396K 0.22% 100
2024
Q4
$1.36M Sell
7,803
-469
-6% -$86.2K 0.14% 129
2024
Q3
$1.63M Buy
+8,272
New +$1.54M 0.14% 128

Other funds holding ABBV

BTG Pactual Asset Management US's ABBV Position: Q1 2026 in Review

BTG Pactual Asset Management US increased its AbbVie (ABBV) stake by 24% in Q1 2026, buying an estimated $1.24M and bringing the position to 28,476 shares worth $6.19M. The position accounts for 0.54% of the portfolio, ranked #55.

BTG Pactual Asset Management US first reported a position in ABBV in Q3 2024 and has held it in 7 quarters since. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • BTG Pactual Asset Management US held 28,476 shares of AbbVie worth $6.19M as of Q1 2026.
  • BTG Pactual Asset Management US bought 5,598 AbbVie shares in Q1 2026, an estimated $1.24M.
  • AbbVie made up 0.54% of BTG Pactual Asset Management US's portfolio in Q1 2026, its #55 holding.
  • BTG Pactual Asset Management US first reported a position in AbbVie in Q3 2024 and has held it in 7 quarters since.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on BTG Pactual Asset Management US's 13F filing for Q1 2026, filed 14 May 2026.